[HTML][HTML] Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies
B Robertson, C Urquhart, I Ford, J Townend… - Journal of Thrombosis …, 2007 - Elsevier
Background and objectives: Patients with myeloproliferative disease (MPD) have an
increased risk of thrombosis. We studied markers of platelet and coagulation activation in a
large cohort of patients with MPD (n= 118) and related this to Janus Kinase 2 (JAK2) V617 F
mutation status, a marker of clonality, and the presence of antiphospholipid antibodies
(APA), all of which have been associated with thrombosis in MPD. Methods: D‐dimer,
thrombin–antithrombin complexes (TAT), prothrombin fragments 1+ 2 (F 1+ 2), soluble E …
increased risk of thrombosis. We studied markers of platelet and coagulation activation in a
large cohort of patients with MPD (n= 118) and related this to Janus Kinase 2 (JAK2) V617 F
mutation status, a marker of clonality, and the presence of antiphospholipid antibodies
(APA), all of which have been associated with thrombosis in MPD. Methods: D‐dimer,
thrombin–antithrombin complexes (TAT), prothrombin fragments 1+ 2 (F 1+ 2), soluble E …